Sunlenca
Sunlenca is a medicine authorised by Swissmedic under authorisation number 68386. The authorisation holder is Gilead Sciences Switzerland Sàrl. The medicinal product code is Synthetic medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 07 July 2023 and the authorisation is limited until 06 July 2028. ATC code J05AX31 places the medicine in the group Antivirals for systemic use.
| Authorisation number | 68386 |
|---|---|
| Name | Sunlenca |
| Full name | Sunlenca, Filmtabletten |
| Authorisation holder | Gilead Sciences Switzerland Sàrl |
| Medicinal product code | Synthetic medicines |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | J05AX31 |
| First authorisation | 07 July 2023 |
| Authorisation validity | 06 July 2028 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Sunlenca, Filmtabletten | A | 07 July 2023 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 5 | Tablette(n) | J05AX31 | 08.03.0. | A |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Sunlenca authorised in Switzerland?
Yes. Sunlenca is authorised by Swissmedic under authorisation number 68386, data as of 01 September 2026. The authorisation is limited until 06 July 2028.
Which dispensing category does Sunlenca have?
Sunlenca is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of Sunlenca?
The authorisation holder is Gilead Sciences Switzerland Sàrl. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.